Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

By Simon A. Jones, J. Scheller, S. Rose‐John. Journal of Clinical Investigation, 2011

676 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/d575d4cd84bbb7b67625595a73ebd6a19e41d3d2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. S. Rose‐John

In Oncology

1. Neeraj Kumari
2. A. Bhatt
3. B. Dwarakanath
4. Asmita Das
5. S. Rose‐John
6. J. Hidalgo
7. Albert Quintana
8. María Erta

In Pathology and Forensic Medicine

1. S. Rose‐John

Citations in the corpus

• Interleukin-6 Family Cytokines. (2018, background): “All cytokines that use gp130 as a receptor subunit were referred to as IL-6 family cytokines or gp130 cytokines (Jones and Rose-John 2002; Jones et al. 2011).”
• Role of interleukin-6 in cancer progression and therapeutic resistance (2016, background): “IL-6 signalling can be targeted in multiple ways, such as the use of specific monoclonal antibodies against IL-6 or IL-6R [15, 19, 31], by”
• IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6 (2012, background): “Since all cells in the body express gp130 [9, 10], theoretically, all cells can be activated by the IL-6/sIL-6R complex.”
• Interleukin-6, a Major Cytokine in the Central Nervous System (2012, background): “Likewise, sgp130 is also of an invaluable utility to specifically block diseases states in which trans-signaling responses exist [232, 234, 241], to the extent that the molecule has recently been structurally-optimized to better antagonize trans-signaling pathologic effects [242].”